

Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma

NCT07221942

Status	RECRUITING
Phase	Phase 2
Sponsor	Fox Chase Cancer Center
Enrollment	97 participants

Key Eligibility Criteria

Inclusion (13)

- Patients must have histologically and radiographically confirmed locally advanced, unresectable urothelial carcinoma.
- Patients should not have received prior systemic therapy for metastatic disease.
- Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria v1.1
- Patients may have received prior neoadjuvant or adjuvant immune checkpoint inhibitor therapy for localized disease and are eligible if they completed the treatment e12 months prior to initiating treatment on this clinical trial.
- ECOG performance status 0-2

... and 8 more (see full listing online)

Exclusion (24)

- Patients who have received prior monomethyl auristatin E (MMAE)-based antibody-drug conjugates (ADCs) for urothelial cancer.
- Grade 2 or higher baseline sensory or motor neuropathy.
- Uncontrolled diabetes (HbA1c \gt 8%)
- Patients with uncontrolled and untreated central nervous system (CNS) metastases.
- Prior radiation to CNS metastases is permitted.

... and 19 more (see full listing online)

Locations (1 total)

Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States